Top-Rated StocksTop-RatedNASDAQ:ASND Ascendis Pharma A/S (ASND) Stock Price, News & Analysis $173.15 +0.09 (+0.05%) Closing price 06/9/2025 04:00 PM EasternExtended Trading$171.00 -2.15 (-1.24%) As of 06/9/2025 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Ascendis Pharma A/S Stock (NASDAQ:ASND) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Ascendis Pharma A/S alerts:Sign Up Key Stats Today's Range$172.00▼$177.0650-Day Range$137.41▼$177.5552-Week Range$111.09▼$183.00Volume484,693 shsAverage Volume493,923 shsMarket Capitalization$10.56 billionP/E RatioN/ADividend YieldN/APrice Target$217.73Consensus RatingBuy Company OverviewAscendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.Read More… Ascendis Pharma A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks65th Percentile Overall ScoreASND MarketRank™: Ascendis Pharma A/S scored higher than 65% of companies evaluated by MarketBeat, and ranked 1003rd out of 1,886 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingAscendis Pharma A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAscendis Pharma A/S has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ascendis Pharma A/S's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ascendis Pharma A/S are expected to grow in the coming year, from ($4.34) to $0.24 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ascendis Pharma A/S is -24.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ascendis Pharma A/S is -24.39, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.33% of the float of Ascendis Pharma A/S has been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Ascendis Pharma A/S has recently decreased by 3.59%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAscendis Pharma A/S does not currently pay a dividend.Dividend GrowthAscendis Pharma A/S does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.33% of the float of Ascendis Pharma A/S has been sold short.Short Interest Ratio / Days to CoverAscendis Pharma A/S has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Ascendis Pharma A/S has recently decreased by 3.59%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment0.79 News SentimentAscendis Pharma A/S has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Ascendis Pharma A/S this week, compared to 7 articles on an average week.Search Interest8 people have searched for ASND on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Ascendis Pharma A/S to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ascendis Pharma A/S insiders have not sold or bought any company stock.Percentage Held by Insiders40.00% of the stock of Ascendis Pharma A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Ascendis Pharma A/S's insider trading history. Receive ASND Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ascendis Pharma A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address ASND Stock News HeadlinesTransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH TrialJune 9 at 7:00 AM | globenewswire.comIs Ascendis Pharma Gaining or Losing Market Support?June 5, 2025 | benzinga.comBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.June 10, 2025 | Crypto 101 Media (Ad)Bank of America Forecasts Strong Price Appreciation for Ascendis Pharma A/S (NASDAQ:ASND) StockJune 5, 2025 | americanbankingnews.comAscendis Pharma ADR Scores Relative Strength Rating UpgradeJune 3, 2025 | msn.comAscendis Pharma stock rises following FDA priority reviewJune 2, 2025 | investing.comAscendis Pharma Rises as FDA Grants Priority Review for Achondroplasia TreatmentJune 2, 2025 | msn.comFDA Accepts TransCon® CNP NDA for Priority ReviewJune 2, 2025 | globenewswire.comSee More Headlines ASND Stock Analysis - Frequently Asked Questions How have ASND shares performed this year? Ascendis Pharma A/S's stock was trading at $137.67 at the beginning of the year. Since then, ASND stock has increased by 25.8% and is now trading at $173.15. View the best growth stocks for 2025 here. How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) released its earnings results on Thursday, May, 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by $0.10. The biotechnology company had revenue of $123.97 million for the quarter, compared to analysts' expectations of $98.56 million. Read the conference call transcript. When did Ascendis Pharma A/S IPO? Ascendis Pharma A/S (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager. Who are Ascendis Pharma A/S's major shareholders? Ascendis Pharma A/S's top institutional shareholders include RA Capital Management L.P. (16.86%), Westfield Capital Management Co. LP (8.99%), T. Rowe Price Investment Management Inc. (5.01%) and Price T Rowe Associates Inc. MD (3.70%). How do I buy shares of Ascendis Pharma A/S? Shares of ASND stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ascendis Pharma A/S investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Meta Platforms (META), Novo Nordisk A/S (NVO) and CrowdStrike (CRWD). Company Calendar Last Earnings5/01/2025Today6/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ASND CIK1612042 Webwww.ascendispharma.com Phone(457) 022-2244Fax45-3694-4010Employees640Year FoundedN/APrice Target and Rating Average Stock Price Target$217.73 High Stock Price Target$289.00 Low Stock Price Target$153.00 Potential Upside/Downside+25.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($6.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$409.12 million Net Margins-104.54% Pretax Margin-102.64% Return on EquityN/A Return on Assets-39.23% Debt Debt-to-Equity RatioN/A Current Ratio1.17 Quick Ratio0.84 Sales & Book Value Annual Sales$368.70 million Price / Sales28.63 Cash FlowN/A Price / Cash FlowN/A Book Value($1.88) per share Price / Book-92.10Miscellaneous Outstanding Shares60,971,000Free Float36,413,000Market Cap$10.56 billion OptionableOptionable Beta0.37 Social Links 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:ASND) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Imagine you're driving down I-45 between Dallas and Houston. You come up behind an 18-wheeler, flick your s...Weiss Ratings | SponsoredWall Street Legend: Crash coming in March—details hereBad News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history give...Chaikin Analytics | SponsoredThe IRS Loophole That Lets You Own Gold Tax-FreeWhat if I told you there's a legal way to own real physical gold and silver—and keep your gains tax-free? N...Advantage Gold | SponsoredTrump’s treachery A few months ago, I released a list of six companies I believed were going to appreciate under Trump’s second ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ascendis Pharma A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Ascendis Pharma A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.